Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Income (2019 - 2025)

Keros Therapeutics' Net Income history spans 7 years, with the latest figure at -$23.5 million for Q4 2025.

  • For Q4 2025, Net Income rose 49.03% year-over-year to -$23.5 million; the TTM value through Dec 2025 reached $87.0 million, up 146.44%, while the annual FY2025 figure was $87.0 million, 146.44% up from the prior year.
  • Net Income reached -$23.5 million in Q4 2025 per KROS's latest filing, down from -$7.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $148.5 million in Q1 2025 to a low of -$53.0 million in Q3 2024.
  • Average Net Income over 5 years is -$21.7 million, with a median of -$28.5 million recorded in 2022.
  • Peak YoY movement for Net Income: crashed 328.21% in 2022, then surged 444.32% in 2025.
  • A 5-year view of Net Income shows it stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then crashed by 56.32% to -$46.5 million in 2023, then grew by 0.92% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Net Income are -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025).